MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

Mark Kerstjens, Emma Driessen, Merel Willekes, Sandra Mimoso Pinhancos, Pauline Schneider, Rob Pieters, Ronald Stam

Research output: Contribution to journalArticleAcademicpeer-review

35 Citations (Scopus)
2 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)14835-14846
Number of pages12
JournalOncotarget
Volume8
Issue number9
DOIs
Publication statusPublished - 2017

Cite this